Ipca Halts Exports To U.S. From FDA-Cited Production Plant In India
This article was originally published in PharmAsia News
Executive Summary
The U.S. FDA has flagged another India production plant for violations, this time an Ipca Laboratories facility in central India, leaving the company only two U.S. FDA-approved plants producing exported generics.